Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 4/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.32 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12813131 | 0.83 | BCHE (0.64) | BCHECDK1SMN1; SMN2USP30NOX1 | |
| SCHEMBL31022783 | 0.83 | BCHE (0.64) | BCHECDK1SMN1; SMN2USP30NOX1 | |
| SCHEMBL12273366 | 0.83 | BCHE (0.49) | BCHEAAK1CDK1SMN1; SMN2USP30 | |
| SCHEMBL2591986 | 0.81 | BCHE (0.47) | BCHECDK1SMN1; SMN2ARUSP30 | |
| SCHEMBL15909028 | 0.76 | NR1H2 (0.43) | BCHESMN1; SMN2USP30NR1H2NR1H3 | |
| SCHEMBL30858752 | 0.76 | BCHE (0.54) | BCHEBACE1 | |
| SCHEMBL30858755 | 0.76 | BCHE (0.54) | BCHEBACE1 | |
| SCHEMBL12273405 | 0.76 | BCHE (0.44) | BCHEAAK1CDK1USP30NOX1 | |
| SCHEMBL2594057 | 0.75 | BCHE (0.41) | BCHECDK1BACE1 | |
| SCHEMBL19744454 | 0.74 | BCHE (0.41) | BCHEGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170151253-A1 | Compounds, Compositions, and Methods for Treating Alzheimer's Disease | Prosetta Antiviral, Inc. | 2017-06-01 | — | — | US | disclosed |
| US-20170151253-A1 | Compounds, Compositions, and Methods for Treating Alzheimer's Disease | Prosetta Antiviral, Inc. | 2017-06-01 | — | — | US | disclosed |
| US-20170151253-A1 | Compounds, Compositions, and Methods for Treating Alzheimer's Disease | Prosetta Antiviral, Inc. | 2017-06-01 | — | — | US | disclosed |
| US-9382221-B2 | Compounds, compositions, and methods for treating alzheimer's disease | PROSETTA ANTIVIRAL INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382221-B2 | Compounds, compositions, and methods for treating alzheimer's disease | PROSETTA ANTIVIRAL INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382221-B2 | Compounds, compositions, and methods for treating alzheimer's disease | PROSETTA ANTIVIRAL INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140315897-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Prosetta Antiviral, Inc. | 2014-10-23 | — | — | US | disclosed |
| US-20140315897-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Prosetta Antiviral, Inc. | 2014-10-23 | — | — | US | disclosed |
| US-20140315897-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Prosetta Antiviral, Inc. | 2014-10-23 | — | — | US | disclosed |
| US-8796448-B1 | Compounds, compositions, and methods for treating Alzheimer's disease | PROSETTA ANTIVIRAL INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796448-B1 | Compounds, compositions, and methods for treating Alzheimer's disease | PROSETTA ANTIVIRAL INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796448-B1 | Compounds, compositions, and methods for treating Alzheimer's disease | PROSETTA ANTIVIRAL INC. (US) | 2014-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151253-A1 | Compounds, Compositions, and Methods for Treating Alzheimer's Disease | PSEN1, APP, PSEN2 | BCHE 12/4885AAK1 100/4885DRD4 70/4885 |
| US-20140315897-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE | PSEN1, APP, PSEN2 | BCHE 12/4885AAK1 100/4885DRD4 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.